Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Chiasson JL, et al. Among authors: laakso m. Diabetologia. 2004 Jun;47(6):969-75; discussion 976-7. doi: 10.1007/s00125-004-1409-4. Epub 2004 May 26. Diabetologia. 2004. PMID: 15164169 Clinical Trial.
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. Chiasson JL, et al. Among authors: laakso m. Diabetes Care. 1998 Oct;21(10):1720-5. doi: 10.2337/diacare.21.10.1720. Diabetes Care. 1998. PMID: 9773737 Clinical Trial.
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, et al. Among authors: laakso m. Lancet. 2006 Sep 23;368(9541):1096-105. doi: 10.1016/S0140-6736(06)69420-8. Lancet. 2006. PMID: 16997664 Free article. Clinical Trial.
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme.
Eriksson J, Lindström J, Valle T, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J. Eriksson J, et al. Among authors: laakso m. Diabetologia. 1999 Jul;42(7):793-801. doi: 10.1007/s001250051229. Diabetologia. 1999. PMID: 10440120 Clinical Trial.
Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.
Laukkanen O, Pihlajamäki J, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study Group. Laukkanen O, et al. Among authors: laakso m. Diabetologia. 2004 May;47(5):871-7. doi: 10.1007/s00125-004-1395-6. Epub 2004 May 1. Diabetologia. 2004. PMID: 15127203 Clinical Trial.
Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion.
Wang J, Kuusisto J, Vänttinen M, Kuulasmaa T, Lindström J, Tuomilehto J, Uusitupa M, Laakso M. Wang J, et al. Among authors: laakso m. Diabetologia. 2007 Jun;50(6):1192-200. doi: 10.1007/s00125-007-0656-6. Epub 2007 Apr 17. Diabetologia. 2007. PMID: 17437080
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.
Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vänttinen M, Stancáková A, Jansson PA, Pellmé F, Holst JJ, Kuulasmaa T, Hribal ML, Sesti G, Stefan N, Fritsche A, Häring H, Pedersen O, Smith U; EUGENE2 Consortium. Laakso M, et al. Diabetologia. 2008 Mar;51(3):502-11. doi: 10.1007/s00125-007-0899-2. Epub 2007 Dec 14. Diabetologia. 2008. PMID: 18080106
1,375 results